Tepotinib · Tepmetko, EMD-1214063

What is Tepotinib?

Tepotinib is an oral kinase inhibitor that targets MET tyrosine kinase, including variants with exon 14 skipping alterations. It inhibits HGF-dependent and -independent MET phosphorylation and downstream signaling, inducing apoptosis in MET-dependent tumor cells and inhibiting tumor growth and metastasis formation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Tepmetko, EMD-1214063, MSC-2156119

Drug type

Small molecule

Targets

MET, melatonin 2 receptor (MTNR1B) (secondary target), imidazoline 1 receptor (secondary target)

Mechanism

Inhibitor of MET

Pathways

MET signal transduction, apoptosis

Therapy area

Oncology

Developer

Emd Serono Inc

In trials of

SMMT

FDA status

Approved as Tepmetko (February 3, 2021), NDA214096 · FDA label

UNII

1IJV77EI07

✅ FDA-approved uses

• Metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations

From the indications section of the FDA label (version of Apr 17, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-Small Cell Lung Cancer

Other drugs acting on MET

Sources

• FDA label (DailyMed)
• FDA label Tepmetko (2025-04-17), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT07619339

Updated Oct 3, 2026.